<?xml version="1.0" encoding="UTF-8"?>
<ref id="B50-ijms-19-01312">
 <label>50.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lee</surname>
    <given-names>J.D.</given-names>
   </name>
   <name>
    <surname>Kumar</surname>
    <given-names>V.</given-names>
   </name>
   <name>
    <surname>Fung</surname>
    <given-names>J.N.</given-names>
   </name>
   <name>
    <surname>Ruitenberg</surname>
    <given-names>M.J.</given-names>
   </name>
   <name>
    <surname>Noakes</surname>
    <given-names>P.G.</given-names>
   </name>
   <name>
    <surname>Woodruff</surname>
    <given-names>T.M.</given-names>
   </name>
  </person-group>
  <article-title>Pharmacological inhibition of complement C5A-C5A1 receptor signalling ameliorates disease pathology in the HSOD1(G93A) mouse model of amyotrophic lateral sclerosis</article-title>
  <source>Br. J. Pharmacol.</source>
  <year>2017</year>
  <volume>174</volume>
  <fpage>689</fpage>
  <lpage>699</lpage>
  <pub-id pub-id-type="doi">10.1111/bph.13730</pub-id>
  <?supplied-pmid 28128456?>
  <pub-id pub-id-type="pmid">28128456</pub-id>
 </element-citation>
</ref>
